HID inhibitors constitute a chemically diverse group of compounds with a common purpose: the manipulation of biological pathways. These inhibitors are meticulously developed to interact with specific protein targets, often enzymes, that play pivotal roles in maintaining cellular homeostasis. By engaging with these targets, HID inhibitors can impede or modify their activity, thereby influencing the progression of biochemical cascades. The design of HID inhibitors involves an in-depth understanding of the target protein's structure and function, enabling the creation of molecules with tailored shapes and properties that facilitate precise binding interactions. These inhibitors can be classified into reversible and irreversible types based on the nature of their interactions with the target protein. Reversible HID inhibitors establish transient bonds with their targets, allowing for the modulation of enzyme activity while retaining the potential for reversibility.
In contrast, irreversible HID inhibitors form covalent bonds with the target protein, resulting in a prolonged and often irreversible impact on its function.
Structurally, HID inhibitors exhibit a wide array of chemical scaffolds, ranging from small organic molecules to more complex entities. The diversity in their structures reflects the intricate design strategies employed to achieve potent and specific interactions with the target proteins. Researchers study HID inhibitors to unravel the intricate molecular mechanisms underlying cellular processes and to potentially identify new avenues for intervention in various biological contexts. By providing insights into the interactions and functions of essential biomolecules, HID inhibitors contribute to expanding our knowledge of the intricate biochemical networks that govern life processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N,N′-(Dithiodi-2,1-ethanediyl)bis[2,5-dichloro-benzenesulfonamide | 927822-86-4 | sc-497219 | 25 mg | $330.00 | ||
Synthetic small molecule inhibiting HIF-1α, possibly useful in HIF-1α-dependent diseases like cancer. | ||||||
PX-478 | 685898-44-6 | sc-507409 | 10 mg | $175.00 | ||
Oral small molecule inhibiting HIF-1α, potential anticancer agent by disrupting hypoxia-driven tumor adaptation. | ||||||
IOX2 | 931398-72-0 | sc-482692 sc-482692A sc-482692B | 5 mg 25 mg 100 mg | $131.00 $566.00 $1613.00 | ||
Potent and selective HIF-1α inhibitor, potential applications in cancer therapy and hypoxia-related disorders. | ||||||
BAY 87-2243 | 1227158-85-1 | sc-507483 | 5 mg | $100.00 | ||
HIF-1α inhibitor with promise in angiogenesis inhibition and tumor growth reduction. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
HIF-1α inhibitor, explored in combination therapies for cancer and heart conditions. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Natural product from fungi inhibiting HIF-1α, insights into HIF-dependent pathways. | ||||||
FM19G11 | 329932-55-0 | sc-364490 sc-364490A | 10 mg 25 mg | $137.00 $519.00 | 1 | |
HIF-1α inhibitor, studied for suppressing Warburg effect in cancer cells. | ||||||